Does the media favor MRVI or CYRX?

In the previous week, Maravai LifeSciences had 3 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Maravai LifeSciences and 2 mentions for CryoPort. Maravai LifeSciences' average media sentiment score of 0.66 beat CryoPort's score of 0.58 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CYRX or ALMR?

In the previous week, CryoPort and CryoPort both had 2 articles in the media. CryoPort's average media sentiment score of 0.58 beat Alamar Biosciences' score of 0.00 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BLFS or CYRX?

In the previous week, CryoPort had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 2 mentions for CryoPort and 1 mentions for BioLife Solutions. CryoPort's average media sentiment score of 0.58 beat BioLife Solutions' score of 0.00 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, CYRX or PSNL?

CryoPort has higher revenue and earnings than Personalis. CryoPort is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $176.18M 4.56 $78.30M -$0.90 N/A Personalis $69.65M 25.30 -$81.27M -$1.09 N/A

Is CYRX or PSNL more profitable?

CryoPort has a net margin of -20.05% compared to Personalis' net margin of -153.84%. CryoPort's return on equity of -7.20% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets CryoPort -20.05% -7.20% -4.30% Personalis -153.84% -46.47% -35.30%

Does the media prefer CYRX or PSNL?

In the previous week, Personalis had 3 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Personalis and 2 mentions for CryoPort. Personalis' average media sentiment score of 0.93 beat CryoPort's score of 0.58 indicating that Personalis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, FTRE or CYRX?

CryoPort has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fortrea $2.72B 0.65 -$986.20M -$0.91 N/A CryoPort $176.18M 4.56 $78.30M -$0.90 N/A

Is FTRE or CYRX more profitable?

Fortrea has a net margin of -3.18% compared to CryoPort's net margin of -20.05%. Fortrea's return on equity of 10.72% beat CryoPort's return on equity. Company Net Margins Return on Equity Return on Assets Fortrea -3.18% 10.72% 2.17% CryoPort -20.05% -7.20% -4.30%

Does the media favor FTRE or CYRX?

In the previous week, Fortrea had 7 more articles in the media than CryoPort. MarketBeat recorded 9 mentions for Fortrea and 2 mentions for CryoPort. CryoPort's average media sentiment score of 0.58 beat Fortrea's score of 0.37 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CryoPort (CYRX) Competitors

$15.86 +0.08 (+0.51%)

As of 04:00 PM Eastern

Compare

CYRX vs. MRVI, ALMR, BLFS, PSNL, and FTRE

Should you buy CryoPort stock or one of its competitors? CryoPort's main competitors and comparable companies include Maravai LifeSciences (MRVI), Alamar Biosciences (ALMR), BioLife Solutions (BLFS), Personalis (PSNL), and Fortrea (FTRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does CryoPort compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

In the previous week, Maravai LifeSciences had 3 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Maravai LifeSciences and 2 mentions for CryoPort. Maravai LifeSciences' average media sentiment score of 0.66 beat CryoPort's score of 0.58 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 9.5% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Maravai LifeSciences has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

Maravai LifeSciences currently has a consensus price target of $6.25, indicating a potential downside of 15.20%. CryoPort has a consensus price target of $18.00, indicating a potential upside of 13.49%. Given CryoPort's stronger consensus rating and higher possible upside, analysts clearly believe CryoPort is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
CryoPort	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

CryoPort has lower revenue, but higher earnings than Maravai LifeSciences. CryoPort is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	10.30	-$130.77M	-$0.52	N/A
CryoPort	$176.18M	4.56	$78.30M	-$0.90	N/A

CryoPort has a net margin of -20.05% compared to Maravai LifeSciences' net margin of -37.07%. CryoPort's return on equity of -7.20% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
CryoPort	-20.05%	-7.20%	-4.30%

Summary

CryoPort beats Maravai LifeSciences on 10 of the 16 factors compared between the two stocks.

How does CryoPort compare to Alamar Biosciences?

CryoPort (NASDAQ:CYRX) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, CryoPort and CryoPort both had 2 articles in the media. CryoPort's average media sentiment score of 0.58 beat Alamar Biosciences' score of 0.00 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alamar Biosciences has a net margin of 0.00% compared to CryoPort's net margin of -20.05%. Alamar Biosciences' return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Alamar Biosciences	N/A	N/A	N/A

CryoPort has higher revenue and earnings than Alamar Biosciences. CryoPort is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.56	$78.30M	-$0.90	N/A
Alamar Biosciences	$74.21M	28.58	-$29.82M	-$1.96	N/A

CryoPort currently has a consensus target price of $18.00, suggesting a potential upside of 13.49%. Alamar Biosciences has a consensus target price of $31.80, suggesting a potential upside of 4.02%. Given CryoPort's stronger consensus rating and higher possible upside, equities research analysts clearly believe CryoPort is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

92.9% of CryoPort shares are owned by institutional investors. 9.5% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

CryoPort beats Alamar Biosciences on 9 of the 14 factors compared between the two stocks.

How does CryoPort compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

BioLife Solutions has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

BioLife Solutions currently has a consensus target price of $31.38, indicating a potential downside of 11.69%. CryoPort has a consensus target price of $18.00, indicating a potential upside of 13.49%. Given CryoPort's stronger consensus rating and higher possible upside, analysts clearly believe CryoPort is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18
CryoPort	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Comparatively, 9.5% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, CryoPort had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 2 mentions for CryoPort and 1 mentions for BioLife Solutions. CryoPort's average media sentiment score of 0.58 beat BioLife Solutions' score of 0.00 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioLife Solutions has a net margin of 53.29% compared to CryoPort's net margin of -20.05%. BioLife Solutions' return on equity of 2.70% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
CryoPort	-20.05%	-7.20%	-4.30%

CryoPort has higher revenue and earnings than BioLife Solutions. CryoPort is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$106.69M	16.27	-$4.59M	$1.16	30.63
CryoPort	$176.18M	4.56	$78.30M	-$0.90	N/A

Summary

BioLife Solutions beats CryoPort on 9 of the 17 factors compared between the two stocks.

How does CryoPort compare to Personalis?

CryoPort (NASDAQ:CYRX) and Personalis (NASDAQ:PSNL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

CryoPort has a net margin of -20.05% compared to Personalis' net margin of -153.84%. CryoPort's return on equity of -7.20% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Personalis	-153.84%	-46.47%	-35.30%

CryoPort has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Personalis has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market.

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are owned by institutional investors. 9.5% of CryoPort shares are owned by company insiders. Comparatively, 4.2% of Personalis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Personalis had 3 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Personalis and 2 mentions for CryoPort. Personalis' average media sentiment score of 0.93 beat CryoPort's score of 0.58 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort currently has a consensus target price of $18.00, indicating a potential upside of 13.49%. Personalis has a consensus target price of $14.54, indicating a potential downside of 13.63%. Given CryoPort's stronger consensus rating and higher possible upside, equities analysts plainly believe CryoPort is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Personalis	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

CryoPort has higher revenue and earnings than Personalis. CryoPort is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.56	$78.30M	-$0.90	N/A
Personalis	$69.65M	25.30	-$81.27M	-$1.09	N/A

Summary

CryoPort beats Personalis on 11 of the 16 factors compared between the two stocks.

How does CryoPort compare to Fortrea?

Fortrea (NASDAQ:FTRE) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Fortrea has a net margin of -3.18% compared to CryoPort's net margin of -20.05%. Fortrea's return on equity of 10.72% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
CryoPort	-20.05%	-7.20%	-4.30%

Fortrea presently has a consensus target price of $20.75, suggesting a potential upside of 11.44%. CryoPort has a consensus target price of $18.00, suggesting a potential upside of 13.49%. Given CryoPort's stronger consensus rating and higher possible upside, analysts clearly believe CryoPort is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
CryoPort	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

92.9% of CryoPort shares are held by institutional investors. 0.7% of Fortrea shares are held by company insiders. Comparatively, 9.5% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CryoPort has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.72B	0.65	-$986.20M	-$0.91	N/A
CryoPort	$176.18M	4.56	$78.30M	-$0.90	N/A

In the previous week, Fortrea had 7 more articles in the media than CryoPort. MarketBeat recorded 9 mentions for Fortrea and 2 mentions for CryoPort. CryoPort's average media sentiment score of 0.58 beat Fortrea's score of 0.37 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortrea has a beta of 1.97, suggesting that its stock price is 97% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

Summary

CryoPort beats Fortrea on 10 of the 16 factors compared between the two stocks.

Get CryoPort News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYRX vs. The Competition

Export

Metric	CryoPort	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$803.31M	$10.02B	$7.24B	$12.90B
Dividend Yield	N/A	1.47%	2.53%	8.56%
P/E Ratio	-17.62	64.84	273.57	25.42
Price / Sales	4.56	112.60	675.05	123.41
Price / Cash	N/A	26.42	76.98	52.08
Price / Book	1.81	36.39	12.91	6.15
Net Income	$78.30M	$56.67B	$3.47B	$349.01M
7 Day Performance	-4.28%	-2.72%	-0.46%	-1.48%
1 Month Performance	2.39%	5.39%	6.40%	2.46%
1 Year Performance	86.59%	26.77%	24.88%	15.76%

CryoPort Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYRX CryoPort	2.238 of 5 stars	$15.86 +0.5%	$18.00 +13.5%	+79.1%	$803.31M	$176.18M	N/A	1,186	Positive News
MRVI Maravai LifeSciences	1.233 of 5 stars	$8.90 -1.1%	$6.25 -29.8%	+211.4%	$2.34B	$185.74M	N/A	610
ALMR Alamar Biosciences	1.6242 of 5 stars	$34.08 +3.2%	$31.80 -6.7%	N/A	$2.29B	$74.21M	N/A	222
BLFS BioLife Solutions	2.6103 of 5 stars	$37.00 -0.6%	$31.38 -15.2%	+41.8%	$1.82B	$96.21M	31.90	440	Positive News
PSNL Personalis	1.7537 of 5 stars	$17.08 -1.0%	$14.54 -14.9%	+247.8%	$1.81B	$69.67M	N/A	400	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYRX) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CryoPort (CYRX) Competitors

CYRX vs. MRVI, ALMR, BLFS, PSNL, and FTRE

How does CryoPort compare to Maravai LifeSciences?

Summary

How does CryoPort compare to Alamar Biosciences?

Summary

How does CryoPort compare to BioLife Solutions?

Summary

How does CryoPort compare to Personalis?

Summary

How does CryoPort compare to Fortrea?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CryoPort (CYRX) Competitors

CYRX vs. MRVI, ALMR, BLFS, PSNL, and FTRE

How does CryoPort compare to Maravai LifeSciences?

Does the media favor MRVI or CYRX?

Do institutionals & insiders believe in MRVI or CYRX?

Which has more volatility and risk, MRVI or CYRX?

Do analysts prefer MRVI or CYRX?

Which has better earnings & valuation, MRVI or CYRX?

Is MRVI or CYRX more profitable?

Summary

How does CryoPort compare to Alamar Biosciences?

Does the media prefer CYRX or ALMR?

Is CYRX or ALMR more profitable?

Which has higher earnings & valuation, CYRX or ALMR?

Do analysts recommend CYRX or ALMR?

Do insiders & institutionals hold more shares of CYRX or ALMR?

Summary

How does CryoPort compare to BioLife Solutions?

Which has more volatility & risk, BLFS or CYRX?

Do analysts prefer BLFS or CYRX?

Do institutionals & insiders have more ownership in BLFS or CYRX?

Does the media favor BLFS or CYRX?

Is BLFS or CYRX more profitable?

Which has preferable valuation and earnings, BLFS or CYRX?

Summary

How does CryoPort compare to Personalis?

Is CYRX or PSNL more profitable?

Which has more volatility and risk, CYRX or PSNL?

Do institutionals and insiders believe in CYRX or PSNL?

Does the media prefer CYRX or PSNL?

Do analysts recommend CYRX or PSNL?

Which has stronger earnings & valuation, CYRX or PSNL?

Summary

How does CryoPort compare to Fortrea?

Is FTRE or CYRX more profitable?

Do analysts recommend FTRE or CYRX?

Do institutionals and insiders hold more shares of FTRE or CYRX?

Which has higher earnings & valuation, FTRE or CYRX?

Does the media favor FTRE or CYRX?

Which has more volatility and risk, FTRE or CYRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools